Dr. Michael Har-Noy Says That Medicine Is Losing The Battle Against Cancer

14 Sep

“Medicine is losing the fight against cancer” says Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, an Israeli biotechnology firm founded in 2004.  Dr. Michael Har-Noy points out that in past thirty years, the incidence of new human malignancies has grown astronomically, affecting nearly one out of two males and one of three females worldwide. Dr. Michael Har-Noy also says that the current cancer rate is 50% higher in males and 25% higher in females than in the last generation.  Physicians at the National Cancer Institute believe that by the year 2050, the incidence of malignant tumors will virtually double.

Dr. Michael Har-Noy goes on to say that in spite of many years of clinical studies and scientific research, improvement in the overall cancer death rate has been negligible, and that reductions in mortality that have been documented are largely secondary to decreased lung cancer deaths from less smoking in the male population – not from improvements in cancer treatments.  Dr. Michael Har-Noy reminds us that the five-year survival rate for all tumors is still about 50% – almost identical to what it was back in 1970.

“Conventional cancer therapy, namely surgery, chemotherapy, and radiation, does tremendous physical and emotional damage to the patient” says Dr. Michael Har-Noy.  Many patients say that traditional cancer treatments are worse than the tumor itself.  Furthermore, the financial strain placed on the medical profession for treating metastatic tumors is astronomically great.  Dr. Michael Har-Noy says that over the past 20 years, the overall estimated yearly cost of cancer therapy has more than quadrupled.  This cost has ballooned to an unbelievable $80 billion in 2005, up from $41 billion in 1995 and $18 billion in 1985.  Furthermore, additional costs due to loss of taxes, wages, and general productivity secondary to metastatic cancer was approximately $100 billion in 1999.

At Immunovative Therapies, Dr. Michael Har-Noy is developing unique drugs that stimulate one’s own immune cells to seek out and kill malignant tumors.  Initial results of a Phase I/II trial indicate that these drugs are very active against many different types of cancers.  Dr. Michael Har-Noy says that definitive randomized Phase II/III trials of these proprietary compounds will soon begin.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: